ABIRATERONE ACETATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2011)
Entry Type: Small molecule
Molecule Category: Salt Prodrug
UNII: EM5OCB9YJ6
Parent Compound: ABIRATERONE

Structure
InChI Key UVIQSJCZCSLXRZ-UBUQANBQSA-N
Smile CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1
InChI
InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C26H33NO2
Molecular Weight 391.56
AlogP 5.97
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 2.0
Polar Surface Area 39.19
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 29.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Cytochrome P450 17A1 inhibitor FDA
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 17 Cytochrome P450 family 17A Cytochrome P450 17A1
- 17-18 - - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 4
17050 - - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Prostatic Neoplasms 4 D011471 ClinicalTrials
Prostatic Neoplasms 4 D011471 ClinicalTrials
Neoplasms 4 D009369 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 4 D064129 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Adrenal Hyperplasia, Congenital 2 D000312 ClinicalTrials
Salivary Gland Neoplasms 2 D012468 ClinicalTrials
Adrenal Hyperplasia, Congenital 2 D000312 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 1 D002289 ClinicalTrials
Renal Insufficiency 1 D051437 ClinicalTrials
Liver Diseases 1 D008107 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
18.16
Investigations
8.33
Vascular disorders
6.9
Gastrointestinal disorders
6.48
Nervous system disorders
5.97
Cardiac disorders
5.67
Injury, poisoning and procedural complications
5.58
Metabolism and nutrition disorders
5.01
Respiratory, thoracic and mediastinal disorders
4.68
Musculoskeletal and connective tissue disorders
4.43
Surgical and medical procedures
3.73
Infections and infestations
3.73
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
3.34
Renal and urinary disorders
3.18
Reproductive system and breast disorders
2.78
Skin and subcutaneous tissue disorders
2.51
Psychiatric disorders
2.41
Blood and lymphatic system disorders
2.06

Cross References

Resources Reference
ChEBI 68639
ChEMBL CHEMBL271227
DrugCentral 4176
EPA CompTox DTXSID3049043
FDA SRS EM5OCB9YJ6
Guide to Pharmacology 9288
KEGG D09701
PubChem 9821849
SureChEMBL SCHEMBL93715
ZINC ZINC000003809191
CONTENTS